You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

 

Online download statistics by month:

Online download statistics by month: June 2023 to July 2025

AbstractFullPdf
Jun 202344144284
Jul 202311291132548
Aug 2023668671169
Sep 2023502503139
Oct 2023536539202
Nov 2023546547167
Dec 2023342344148
Jan 2024208208115
Feb 2024258259106
Mar 2024364365176
Apr 2024341341175
May 2024316315120
Jun 2024364367153
Jul 2024411414115
Aug 202427427199
Sep 2024267267461
Oct 2024363364127
Nov 2024337338107
Dec 202431231388
Jan 2025372372121
Feb 2025317317267
Mar 2025295296170
Apr 2025333334186
May 2025225225151
Jun 202523323595
Jul 2025220
Total975697814289